Issues
-
Cover Image
Cover Image
Changes in the levels of blood immune markers can help predict multiple myeloma progression. In the nested case-control study starting on page 383, Herdenberg and colleagues investigated the associations between the pre-diagnostic serum levels of candidate biomarkers and future multiple myeloma risk, as well as marker changes over time. The cover image, adapted from Supplementary Fig. S1, shows sample collection time for cases before multiple myeloma diagnosis. Interestingly, samples were collected up to 42 years before multiple myeloma diagnosis. The colors distinguish between first and additional sample collected. In this study, TGF-α levels decreased significantly closer to the diagnosis in multiple myeloma patients which warrants further investigation. The decrease in TGF-α levels may reflect subtle microenvironmental changes related to multiple myeloma progression. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
Highlights from the Literature
Spotlight
Research Articles
Prediagnostic Serum Immune Marker Levels and Multiple Myeloma: A Prospective Longitudinal Study Using Samples from the Janus Serum Bank in Norway
This study observed a decline in TGF-α serum levels closer to multiple myeloma diagnosis, which may aid in predicting multiple myeloma progression and early detection, although validation in other longitudinal cohorts is needed.
From Therapy to Cancer Prevention Using HRD Testing on Patients with High-grade Ovarian Cancer
Genomic instability status (HRD testing), which is essential for making therapy choices, is useful to identify inherited ovarian cancers. Identifying these families with high cancer risk is critical for implementing targeted cancer prevention strategies.
Randomized Study of Metformin and Intensive Lifestyle Intervention on Cancer Incidence over 21 Years of Follow-up in the Diabetes Prevention Program
This study examines both metformin and ILS intervention as primary cancer prevention interventions in people at high risk for type 2 diabetes.
Cancer Incidence and Survival after Emergency Department Care in the U.S. Midwest: An Opportunity for Cancer Interception
This cohort analysis shows that cancer incidence over 6 years was lower among participants after an ED visit than among matched non-ED participants, whereas cancer-specific mortality was higher in the ED group (HRAdjusted = 1.76; 95% CI, 1.49–2.08; P = 3.62 × 10−11), suggesting the potential benefit of preventive interventions.
Implementing a Tribally Engaged Lung Cancer Screening Pilot Program in Rural Oklahoma
Our community-engaged, multicomponent, and multilevel pilot implementation study significantly improved lung cancer screening rates in a rural, tribal health system. A key feature of this pilot study was a centralized screening coordination service supported by a population screening registry. We believe that our study is replicable in other settings.
Advertisement
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds